The Silent Accomplice: Why **Triglycerides and Cardiovascular Disease** Demand a Second Look

The arteries do not lie, even when the charts do. A patient sits in the consultation room, believing they are safe. Their low-density lipoprotein (LDL)—the notorious ‘bad’ cholesterol—has been hammered down to negligible levels by statins. They eat well. They exercise. Yet, inside the vessel walls, a silent accumulation continues. It is not the waxy buildup we have spent decades fearing, but a different, greasier substance. This is the domain of ‘residual risk’, a clinical euphemism for a terrifying reality: a person can fix the primary problem and still suffer the catastrophe.

For years, this secondary actor was ignored. Triglycerides were viewed as mere bystanders, innocent passengers in the blood that simply rose alongside other risks. We were wrong. These fats, specifically the triglyceride-rich lipoproteins and their remnants, circulate like ghost ships. They are smaller, denser, and carry a payload of cholesterol that slips past traditional defences. They burrow into the endothelium, sparking inflammation and plaque formation where we least expect it. The villain here is not just the fat itself, but our own oversight—the blind spot in standard cardiology that leaves millions vulnerable to a heart attack they thought they had prevented. The blood remains thick with threat, even when the lab report looks clean.

Re-evaluating Triglycerides and Cardiovascular Disease

The plot twist in this biological thriller comes from our genes. As this review highlights, the scientific community is finally looking past association to find causation. Mendelian randomisation studies—nature’s own clinical trials—suggest that these remnant lipoproteins are not merely present at the scene of the crime; they are helping to commit it. The data indicates that Apolipoprotein B, the structural backbone of these particles, may be the principal driver of the damage.

This realisation forces a pivot. If statins are the hammer, we now need a scalpel. The review examines emerging tools designed to dismantle this specific threat. Traditional fibrates have offered mixed results, often failing to change the final outcome for the patient. However, a new generation of ‘heroes’ is entering the clinic. Therapies targeting ApoC-III and ANGPTL3 are showing a robust ability to clear these fats from the circulation. These agents work with precision, stripping away the excess inhibition that keeps triglycerides high.

Yet, in the human endeavour of medicine, excitement must be tempered with patience. While the biological mechanism is sound, and the lipid levels drop precipitously, the ultimate proof is still absent. We know these drugs clean the blood; we do not yet know for certain if they save the heart. The review notes that outcome data remains limited. Until ongoing trials conclude, these potent inhibitors represent a promising hypothesis rather than a guaranteed cure. For the high-risk patient—those with diabetes or metabolic syndrome—the hope is that addressing this residual risk will finally close the door on the silent killer.